Monitoring Immune Health With Subcutaneous Daratumumab
Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.
Subcutaneous Daratumumab Provides Speedier Multiple Myeloma Treatment
Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.
Subcutaneous Daratumumab Requires Less Time, Premed in Multiple Myeloma
Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says Heather Wenberg, BSN, RN, OCN.
Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden
Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.
Education Reassures Patients With MM Receiving Subcutaneous Daratumumab
Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.
Injection Time Can Encourage Bonding During Myeloma Care
The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.
Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma
A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.
Subcutaneous Daratumumab May Be More Feasible for Older Patients With MM
Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.
Intraoral Photobiomodulation Device Safe, Reduces Oral Mucositis in HNC
Fixed-Duration Mosunetuzumab/Polatuzumab Active in R/R MCL
Zidesamtinib Active, Safe in Pretreated ROS1+ Advanced NSCLC
Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL
